

**SPARSENTAN PUBLICATIONS**

<b>Title</b>	<b>Meeting/Citation</b>
<b>2023</b>	
Superior Proteinuria Reduction With Sparsentan in Immunoglobulin A Nephropathy (IgAN): PROTECT Study Interim Analysis	<b>Mini-lecture</b> at the 60 <sup>th</sup> European Renal Association (ERA) congress, June 15-18, 2023, Milan, Italy (and virtual)
Estimating delay in time to kidney failure or death for treatment effects on proteinuria in IgA nephropathy	<b>Mini-lecture</b> at the 60 <sup>th</sup> European Renal Association (ERA) congress, June 15-18, 2023, Milan, Italy (and virtual)
Modelling long-term outcomes for patients with immunoglobulin A Nephropathy (IgAN) from short-term proteinuria data	<b>Mini-lecture</b> at the 60 <sup>th</sup> European Renal Association (ERA) congress, June 15-18, 2023, Milan, Italy (and virtual)
Alport Syndrome Natural History from the RaDaR Registry: Associations with Gene, Variant Type and Sex	<b>Mini-lecture</b> at the 60 <sup>th</sup> European Renal Association (ERA) congress, June 15-18, 2023, Milan, Italy (and virtual)
The natural history of IgA nephropathy in the German Chronic Kidney Disease (GCKD) cohort	<b>Focused oral</b> at the 60 <sup>th</sup> European Renal Association (ERA) congress, June 15-18, 2023, Milan, Italy (and virtual)
Matching-Adjusted Indirect Comparison of Sparsentan versus Delayed-Release Formulation Budesonide for Proteinuria Reduction in Adult Patients with IgA Nephropathy	<b>Focused oral</b> at the 60 <sup>th</sup> European Renal Association (ERA) congress, June 15-18, 2023, Milan, Italy (and virtual)
Outcomes in SRNS (FSGS) patients in the UK RaDaR Idiopathic Nephrotic Syndrome Registry and their relationship with time-averaged proteinuria	<b>Moderated oral</b> at the 60 <sup>th</sup> European Renal Association (ERA) congress, June 15-18, 2023, Milan, Italy (and virtual)
Rapid and Sustained Proteinuria Reduction With Sparsentan in Immunoglobulin A Nephropathy (IgAN): PROTECT Study Interim Results	<b>Poster and podium presentation</b> at the National Kidney Foundation (NKF) Spring Clinical Meetings, April 11-15, 2023 Austin, TX
Long-Term Sparsentan Treatment in FSGS in the	<b>Poster presentation</b> at the National Kidney Foundation (NKF) Spring Clinical Meetings, April 11-15, 2023 Austin, TX

DUET Open-Label Extension (OLE)	
Long-Term Sparsentan Treatment in Young Patients With Focal Segmental Glomerulosclerosis (FSGS) in the DUET Open-Label Extension (OLE)	<b>Poster presentation</b> at the National Kidney Foundation (NKF) Spring Clinical Meetings, April 11-15, 2023 Austin, TX
Proteinuria and its association with disease progression in IgA nephropathy: Analysis of the UK National RaDaR IgA nephropathy cohort	<b>Poster presentation</b> at the National Kidney Foundation (NKF) Spring Clinical Meetings, April 11-15, 2023 Austin, TX
Sparsentan Reduces Proteinuria In Patients With Immunoglobulin A Nephropathy (IgAN): Interim Results Of The Protect Study	<b>Oral presentation</b> at the World Congress of Nephrology (WCN), March 30 – April 2, 2023; Bangkok, Thailand
Immunoglobulin A Nephropathy (IgAN) Patient Baseline Characteristics in Asian Versus Non-Asian Regions in the Sparsentan PROTECT Study	<b>Poster presentation</b> at the World Congress of Nephrology (WCN), March 30 – April 2, 2023; Bangkok, Thailand
Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)	<b>Poster presentation</b> at the World Congress of Nephrology (WCN), March 30 – April 2, 2023; Bangkok, Thailand
Sparsentan, The Dual Endothelin/Angiotensin II Receptor Antagonist improves kidney function and lifespan and protects against hearing loss in Alport mice with developed renal structural changes	<b>Poster presentation</b> at the Association for Research in Otolaryngology (ARO) conference, Feb 11-15, 2023, Orlando, FL
<b>2022</b>	
Sparsentan, The Dual Endothelin/Angiotensin II Receptor Antagonist improves kidney function and lifespan and protects against hearing loss in Alport mice with developed renal structural changes	<b>Poster presentation</b> at the 52nd National Congress of the Spanish Society of Nephrology, Nov 12-14, 2022, Granada, Spain  Session: Hereditary Kidney Diseases   Basic nephrology Day Session Time: 12/11/2022   16:00 - 17:00h Presentation time: 16:50h E-Poster No.: E-011
The dual ETAR/AT1R antagonist Sparsentan protects from glomerular	<b>Oral presentation</b> at the 52nd National Congress of the Spanish Society of Nephrology, Nov 12-14, 2022, Granada, Spain

hypercellularity and associated immune/inflammatory gene-network-activity in a model of IgA nephropathy (IgAN)	
Sparsentan improves glomerular blood flow and augments protective tissue remodeling in focal segmental glomerulosclerosis (FSGS)	<b>Oral presentation</b> at the 52nd National Congress of the Spanish Society of Nephrology, Nov 12-14, 2022, Granada, Spain
Evaluating Predictors of Structural Features in Kidney Biopsies from Adults with Focal Segmental Glomerulosclerosis	<b>Poster presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022, Orange County Convention Center, Orlando, FL  Session Title: Glomerular Diseases: Clinical, Outcomes, Trials - II [PO1303-2] Session Date, Time: November 4, 2022 from 10:00 AM to 12:00 PM Poster Board #: FR-PO662
A Retrospective Analysis of Cardiovascular Disease (CVD) Events in Prevalent Patients with Focal Segmental Glomerulosclerosis (FSGS) in the US	<b>Poster presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022, Orange County Convention Center, Orlando, FL  Session Title: Glomerular Diseases: Clinical, Outcomes, Trials - III [PO1303-3] Session Date, Time: November 5, 2022 from 10:00 AM to 12:00 PM Poster Board #: TH-PO702
Predictors of Progression to Kidney Failure in Patients with Focal Segmental Glomerulosclerosis	<b>Poster presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022, Orange County Convention Center, Orlando, FL  Session Title: Glomerular Diseases: Clinical, Outcomes, Trials - I [PO1303-1] Session Date, Time: November 3, 2022 from 10:00 AM to 12:00 PM Poster Board #: TH-PO478
Development of a Treatment Response Prediction Strategy for Sparsentan in Glomerular Disease	<b>Poster presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022, Orange County Convention Center, Orlando, FL  Session Title: Glomerular Diseases: Podocyte Biology - I [PO1304-1] Session Date, Time: November 4, 2022 from 10:00 AM to 12:00 PM Poster Board #: FR-PO724
Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: Open-label Drug-Drug Interaction Study in Healthy Adults	<b>Poster presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022, Orange County Convention Center, Orlando, FL  Session Title: Pharmacology [PO1900] Session Date, Time: November 4, 2022 from 10:00 AM to 12:00 PM Poster Board #: FR-PO217
Health State Utility Values for Immunoglobulin A Nephropathy (IgAN)	<b>Poster presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022, Orange County Convention Center, Orlando, FL  Session Title: Glomerular Diseases: Clinical, Outcomes, Trials - I [PO1303-1] Session Date, Time: November 3, 2022 from 10:00 AM to 12:00 PM Poster Board #: TH-PO496
Differentiating primary and secondary FSGS using non-invasive urine biomarkers	<b>Poster presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022, Orange County Convention Center, Orlando, FL

	<p>Session Title: CKD: Epidemiology, Risk Factors, Prevention - II [PO2201-2]  Session Date, Time: November 4, 2022 from 10:00 AM to 12:00 PM  Poster Board #: FR-PO913</p>
<p>The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN) on Patients and Caregivers Study (HONUS): Preliminary Results for IgAN in the United States (US)</p>	<p><b>Poster presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022, Orange County Convention Center, Orlando, FL</p> <p>Session Title: Glomerular Diseases: Clinical, Outcomes, Trials - III [PO1303-3]  Session Date, Time: November 5, 2022 from 10:00 AM to 12:00 PM  Poster Board #: SA-PO699</p>
<p>Sparsentan Improves Glomerular Endothelial and Podocyte Functions and Augments Protective Tissue Repair in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS)</p>	<p><b>Oral presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022 Orange County Convention Center, Orlando, FL</p> <p>Session Title: Glomerular Diseases: From Bench to Bedside [OR1300-1]  Session Date/Time: November 4, 2022 from 4:30 PM to 6:00 PM  Session Room: W414 (Orange County Convention Center, West Building)  Abstract Publication #: FR-OR56  Presentation Time: 5:15 PM to 5:24 PM (6 minutes for presentation, 3 minutes for Q&amp;A)</p>
<p>Long-Term Efficacy and Safety of Sparsentan in FSGS: 240-Week Analysis of the DUET Open-Label Extension</p>	<p><b>Oral presentation</b> at the American Society of Nephrology (ASN), Nov 1-6, 2022 Orange County Convention Center, Orlando, FL</p> <p>Session Title: Glomerular Diseases: From Bench to Bedside [OR1300-1]  Session Date/Time: November 4, 2022 from 4:30 PM to 6:00 PM  Session Room: W414 (Orange County Convention Center, West Building)  Abstract Publication #: FR-OR57  Presentation Time: 5:24 PM to 5:33 PM (6 minutes for presentation, 3 minutes for Q&amp;A)</p>
<p>Physiologically Based Pharmacokinetic (PBPK) Model of Sparsentan to Evaluate Drug-Drug Interaction Potential</p>	<p><b>Poster presentation</b> at the American Conference on Pharmacometrics, October 30-November 2, 2022 Aurora, CO</p>
<p>Sparsentan, the dual endothelin and angiotensin receptor antagonist (DEARA), improves kidney function and lifespan and protects against hearing loss in Alport mice with developed renal structural changes</p>	<p><b>Poster presentation</b> at the German Society of Nephrology 14th Annual Congress 2022 (DGfN2022), 6-9 October 2022, Berlin, Germany</p>
<p>The Dual Endothelin Angiotensin Receptor Antagonist (DEARA) Sparsentan Protects From Glomerular Hypercellularity</p>	<p><b>Poster presentation</b> at the German Society of Nephrology 14th Annual Congress 2022 (DGfN2022), 6-9 October 2022, Berlin, Germany</p>

and Associated Immune/Inflammatory Gene-Network-Activity in a Model of IgA Nephropathy	
Sparsentan Improves Glomerular Blood Flow and Augments Protective Tissue Remodeling in Mouse Models of Focal Segmental Glomerulosclerosis (FSGS)	<b>Poster presentation</b> at the German Society of Nephrology 14th Annual Congress 2022 (DGfN2022), 6-9 October 2022, Berlin, Germany
Sparsentan for Treatment of Pediatric Patients With Selected Proteinuric Glomerular Diseases: Design of the Phase 2 EPPIK Study	<b>Poster presentation</b> at the Italian Society for Pediatric Nephrology (SINePe), in late September, Florence, Italy
Sparsentan, The Dual Endothelin/Angiotensin II Receptor Antagonist improves kidney function and lifespan and protects against hearing loss in Alport mice with developed renal structural changes	<b>Oral presentation</b> at The Molecular Biology of Hearing and Deafness Conference (MBHD), Iowa City, May 24 - 27, 2022
Sparsentan for Treatment of Pediatric Patients With Selected Proteinuric Glomerular Diseases: Design of the Phase 2 EPPIK Study	<b>Oral presentation</b> at the 45 Congreso Nacional Neurología Pediátrica (AENP), May 25-28, A Coruña, Spain Presentation - May 26
Sparsentan for Treatment of Pediatric Patients With Selected Proteinuric Glomerular Diseases: Design of the Phase 2 EPPIK Study	<b>Poster presentation</b> at the Polish Society of Pediatric Nephrology (PTNFD), May 13-14, 2022, Poznan, Poland
Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Subjects with Focal Segmental Glomerulosclerosis (FSGS)	<b>Poster presentation</b> at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Online Annual Meeting; March 16-18, 2022
Focal Segmental Glomerulosclerosis in Adults: A Retrospective Analysis of US Prevalence and Impact of Proteinuria and Kidney Function Decline on Healthcare Resource Utilization (HRU) and Costs	<b>Poster presentation</b> at ISPOR 2022; May 15-May 18, 2022; Washington, DC USA Area and Virtual  Abstract available at: <a href="https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3461/117466">https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3461/117466</a>
IgA Nephropathy in Adults: A Retrospective Analysis of US	<b>Poster presentation</b> at ISPOR 2022; May 15-May 18, 2022; Washington, DC USA Area and Virtual

Prevalence and Impact of Proteinuria and Kidney Function Decline on Healthcare Resource Utilization (HRU) and Costs	Abstract available at: <a href="https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3462/117477">https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3462/117477</a>
A USRDS retrospective cohort Study: epidemiology, treatment modalities, and burden of end-stage kidney disease attributed to focal segmental glomerulosclerosis (FSGS)	<b>Poster presentation</b> at ISPOR 2022; May 15-May 18, 2022; Washington, DC USA Area and Virtual  Abstract available at: <a href="https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3463/116979">https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3463/116979</a>
A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-Stage Kidney Disease Attributed to Immunoglobulin A Nephropathy (IgAN)	<b>Poster presentation</b> at ISPOR 2022; May 15-May 18, 2022; Washington, DC USA Area and Virtual  Abstract available at: <a href="https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3459/117008">https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3459/117008</a>
Baseline Characteristics of Patients Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis (DUPLEX)	<b>Mini-Oral presentation</b> at the 59 <sup>th</sup> European Renal Association (ERA) Congress 2022; May 19 – May 22, 2022; Paris, France  Abstract available at: <i>Nephrology Dialysis Transplantation</i> , Volume 37, Issue Supplement_3, May 2022, gfac067.053, <a href="https://doi.org/10.1093/ndt/gfac067.053">https://doi.org/10.1093/ndt/gfac067.053</a>
Baseline Characteristics of Adults Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)	<b>Mini-Oral presentation</b> at the 59 <sup>th</sup> European Renal Association (ERA) Congress 2022; May 19 – May 22, 2022; Paris, France  Abstract available at: <i>Nephrology Dialysis Transplantation</i> , Volume 37, Issue Supplement_3, May 2022, gfac067.008, <a href="https://doi.org/10.1093/ndt/gfac067.008">https://doi.org/10.1093/ndt/gfac067.008</a>
Sparsentan Protects the Glomerular Basement Membrane and Glycocalyx, and Attenuates Proteinuria in a Rat Model of Focal Segmental Glomerulosclerosis (FSGS)	<b>Mini-Oral presentation</b> at the 59 <sup>th</sup> European Renal Association (ERA) Congress 2022; May 19 – May 22, 2022; Paris, France  Abstract available at: <i>Nephrology Dialysis Transplantation</i> , Volume 37, Issue Supplement_3, May 2022, gfac067.054, <a href="https://doi.org/10.1093/ndt/gfac067.054">https://doi.org/10.1093/ndt/gfac067.054</a>
Sparsentan, the Dual Endothelin and Angiotensin Receptor Antagonist (DEARA), Protects from the Development of Albuminuria and Renal Injury to a Greater Extent than Losartan in the	<b>Mini-Oral presentation</b> at the 59 <sup>th</sup> European Renal Association (ERA) Congress 2022; May 19 – May 22, 2022; Paris, France  Abstract available at: <i>Nephrology Dialysis Transplantation</i> , Volume 37, Issue Supplement_3, May 2022, gfac067.060, <a href="https://doi.org/10.1093/ndt/gfac067.060">https://doi.org/10.1093/ndt/gfac067.060</a>

gddY Mouse Model of IgA Nephropathy; a 16 Week Study	
Sparsentan for Treatment of Pediatric Patients with Selected Proteinuric Glomerular Diseases: Design of the Phase 2 EPPIK Study	<b>Poster presentation</b> at the Congrès de la Société de Néphrologie Pédiatrique 2022; 2-4 June 2022; Lyon, France  Abstract available at:
Sparsentan for Treatment of Pediatric Patients with Selected Proteinuric Glomerular Diseases: Design of the Phase 2 EPPIK Study	<b>Poster presentation</b> at the Royal College of Paediatrics and Child Health Annual Conference 2022; 28-30 June 2022; Liverpool, UK  Abstract available at:
<b>2021</b>	
Gene Editing in Alport Syndrome by CRISPR/Cas9: Moving Towards COL4A5 Mouse Model	<b>Oral presentation</b> at The 2021 Online International Workshop on Alport Syndrome, November 30-December 4, 2021; Virtual  Abstract available at: <a href="S:\MedAffairs\Publications\Sparsentan\Abstracts\2021\Alport Workshop 2021">S:\MedAffairs\Publications\Sparsentan\Abstracts\2021\Alport Workshop 2021</a>
Sparsentan for Treatment of Pediatric Patients with Selected Proteinuric Glomerular Diseases: Design of the Phase 2 EPPIK Study	<b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Pediatric Nephrology: AKI, Dialysis, Transplant, CKD, and Nephrotic Syndrome  Abstract PO1980 available at: <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllid=3604632">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllid=3604632</a>
The Dual Endothelin Angiotensin Receptor Antagonist (DEARA) Sparsentan Protects from Glomerular Hypercellularity and Associated Immune/Inflammatory Gene Network Activity in a Model of IgA Nephropathy	<b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Immunology and Inflammation in IgANP, C3GP, TMA, and Nephrotic Diseases  Abstract PO1454 available at: <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllid=3604908">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllid=3604908</a>
Importance of Endothelin-1 (ET) Versus Angiotensin II (AngII) in Renal Hemodynamics and Tissue Remodeling Demonstrated by Sparsentan in Normal and TRPC6 Mice	Accepted as "Oral Presentation" at ASN 2021/withdrawn
Sparsentan, the Dual Endothelin Angiotensin Receptor Antagonist (DEARA), Improves Kidney Function and Lifespan and Protects Against Hearing	<b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Genetic Diseases of the Kidneys: Non-Cystic - I  Abstract PO1299 available at: <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllid=3602841">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllid=3602841</a>



Loss in Alport Mice with Developed Renal Structural Changes	
Clinicopathological Characteristics of Adult Patients in the United States with Focal Segmental Glomerulosclerosis (FSGS)	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Clinical Features and Outcomes in Nephrotic Syndromes and Complement-Mediated Diseases</p> <p>Abstract PO1531 available at:  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604201">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604201</a></p>
Natural History of Focal Segmental Glomerulosclerosis (FSGS): The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Clinical Features and Outcomes in Nephrotic Syndromes and Complement-Mediated Diseases</p> <p>Abstract PO1529 available at:  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604316">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604316</a></p>
Clinicopathological Characteristics of Adult IgA Nephropathy: A Retrospective Cohort Study	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Clinicopathological Features and Outcomes in IgAN, Lupus Nephritis, and Vasculitis</p> <p>Abstract PO1576 available at:  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604166">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604166</a></p>
Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of FSGS and IgAN on Patients and Caregivers: The HONUS Rationale and Study Design	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Immunology and Inflammation in IgANP, C3GP, TMA, and Nephrotic Diseases</p> <p>Abstract PO1479 available at:  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604722">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604722</a></p>
Natural History of IgA Nephropathy: Analysis of a UK National RaDaR IgA Nephropathy Cohort	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Clinicopathological Features and Outcomes in IgAN, Lupus Nephritis, and Vasculitis</p> <p>Abstract PO1577 available at:  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604660">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604660</a></p>
Proteinuria End Points and Association with Renal Survival in FSGS: Analysis of the UK National RaDaR Idiopathic Nephrotic Syndrome Cohort	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Clinical Features and Outcomes in Nephrotic Syndromes and Complement-Mediated Diseases</p> <p>Abstract PO1530 available at:  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604328">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controllId=3604328</a></p>



Clinicopathological Characteristics of Focal Segmental Glomerulosclerosis (FSGS) in a Pediatric Patient Population	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Publication Only</p> <p>Abstract PUB261 available at:  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3604710">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3604710</a></p>
DEFINE Physicians: An International Delphi Survey to Identify Consensus in the Care of Patients with FSGS or Idiopathic Nephrotic Syndrome	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Treatment and Outcomes</p> <p>Abstract PO1643 available at:  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3604861">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3604861</a></p>
An International Delphi Survey on IgA Nephropathy: Results from the DEFINE Physicians Study	<p><b>ePoster presentation</b> at ASN Kidney Week 2021, November 4-7, 2021; Virtual Session Title: Glomerular Diseases: Treatment and Outcomes</p> <p>Abstract PO1641 available at (authors listed incorrectly in ASN program; Floege J should be first author and Vivarelli M should be last author):  <a href="https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3604214">https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3604214</a></p>
Sparsentan improves glomerular blood flow and augments protective tissue remodeling in mouse model of focal segmental glomerulosclerosis (FSGS)	<p>Accepted as “Free Communication” at ERA-EDTA 2021 (10 mins followed by a 3 min. Q&amp;A)  Session Time: June 7, 2021 17:00-18:30 CEST</p> <p><a href="https://www.era-edta.org/en/virtual-meeting/#!resources/fc-016-sparsentan-improves-glomerular-blood-flow-and-augments-protective-tissue-remodeling-in-mouse-models-of-focal-segmental-glomerulosclerosis-fsgs-27788531-978f-4b98-854c-0e8f144443d7">https://www.era-edta.org/en/virtual-meeting/#!resources/fc-016-sparsentan-improves-glomerular-blood-flow-and-augments-protective-tissue-remodeling-in-mouse-models-of-focal-segmental-glomerulosclerosis-fsgs-27788531-978f-4b98-854c-0e8f144443d7</a></p>
The treatment effect of RAS blockade on proteinuria in IgA nephropathy patients as a surrogate for renal events and decline in eGFR: An analysis of randomized controlled trials	<p>Accepted as “mini-oral” (3-4 pptx slides with audio up to 5 mins pre-recorded at ERA-EDTA</p> <p><a href="https://academic.oup.com/ndt/article/36/Supplement_1/gfab104.0014/6289321">https://academic.oup.com/ndt/article/36/Supplement_1/gfab104.0014/6289321</a></p>
Estimating delay in time to ESKD for treatment effects on proteinuria in IgA nephropathy and FSGS	<p>Accepted as Moderated “mini-oral” (up to 6 pptx slides with audio up to 3 mins followed by a 3-min discussion) at ERA-EDTA</p> <p><a href="https://academic.oup.com/ndt/article/36/Supplement_1/gfab104.004/6289667">https://academic.oup.com/ndt/article/36/Supplement_1/gfab104.004/6289667</a></p>
<b>2020</b>	
The Dual Endothelin/Angiotensin II Receptor (ETAR/ AT1R) Antagonist Sparsentan Slows Renal Disease, Improves Lifespan, and Attenuates	<p><b>ePoster presentation</b> at ASN Kidney Week 2020, October 20-25, 2020; Denver, CO  Session Title: Glomerular Diseases: Clinical, Outcomes, and Trials – 2</p> <p>Abstract available at:</p>

<p>Hearing Loss in Alport Mice: Comparison with Losartan and Atrasentan [ENCORE]</p>	<p><a href="https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3441011">https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3441011</a></p>
<p>The Dual Endothelin ETA and Angiotensin AT1 Receptor Blocker Sparsentan Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy [ENCORE]</p>	<p><b>ePoster presentation</b> at ASN Kidney Week 2020, October 20-25, 2020; Denver, CO Session Title: Glomerular Diseases: IgA, C3G, and FSGS</p> <p>Abstract available at: <a href="https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3442475">https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3442475</a></p>
<p>Efficacy and safety of immunosuppressive therapies in primary FSGS: A systematic review and meta-analysis</p>	<p><b>ePoster presentation</b> at ASN Kidney Week 2020, October 20-25, 2020; Denver, CO Session Title: Glomerular Diseases: Clinical, Outcomes, and Trials – 2</p> <p>Abstract available at: <a href="https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3445162">https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3445162</a></p>
<p>Efficacy and safety of RAAS inhibitors (ACE and ARB) therapies in primary FSGS treatment: A systematic review and meta-analysis</p>	<p><b>ePoster presentation</b> at ASN Kidney Week 2020, taking October 20-25, 2020; Denver, CO Session Title: Glomerular Diseases: Clinical, Outcomes, and Trials – 2</p> <p>Abstract available at: <a href="https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3444205">https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3444205</a></p>
<p>Complete Remission of Proteinuria in Patients with FSGS Treated with Sparsentan (SPAR), a Dual Endothelin and Angiotensin Receptor Antagonist, in the DUET Trial</p>	<p><b>Oral presentation</b> at ASN Kidney Week 2020, taking place October 20-25, 2020; Denver, CO Session Title: Halfway Through the Marathon: Clinical Candidates in Development [OR1203] Session Date/Time: October 25, 2020 from 5:00 PM to 7:00 PM</p> <p>Abstract available at: <a href="https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3441246">https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controllId=3441246</a></p>
<p>The Dual Endothelin ETA and Angiotensin AT1 Receptor Blocker Sparsentan Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy [ENCORE]</p>	<p><b>Poster</b> presented at German Society of Nephrology (DGfN) congress, taking place October 1-4, 2020, Berlin, Germany</p> <p>Abstract available at: <a href="https://www.nephrologie2020.de/index/programm/poster/pg10/experimentelle-nephrologie-3-p076-p084.html">https://www.nephrologie2020.de/index/programm/poster/pg10/experimentelle-nephrologie-3-p076-p084.html</a></p>

The Dual ETAR/AT1R Blocker Sparsentan Slows Renal Disease, Improves Lifespan, and Attenuates Hearing Loss in Alport Mice: Comparison with Losartan and Atrasentan	<b>Poster</b> presented at German Society of Nephrology (DGfN) congress, taking place October 1-4, 2020, Berlin, Germany  Abstract available at: <a href="https://www.nephrologie2020.de/index/programm/poster/pg08/experimentelle-nephrologie-1-p058-p066.html">https://www.nephrologie2020.de/index/programm/poster/pg08/experimentelle-nephrologie-1-p058-p066.html</a>
The Dual Endothelin ETA and Angiotensin AT1 Receptor Blocker Sparsentan Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy [ENCORE]	<b>Abstract (encore) accepted for presentation</b> at the 63 <sup>rd</sup> Annual Meeting of the Japanese Society of Nephrology, Aug 19-21 2020, in Yokohama, Japan  Due to COVID-19, authors of accepted abstracts for regular session (both oral and poster) were not asked to develop a presentation, but the abstract appears in the digital abstract book.
The Dual ETAR/AT1R Blocker Sparsentan Slows Renal Disease, Improves Lifespan, and Attenuates Hearing Loss in Alport Mice: Comparison with Losartan	<b>Live Streaming Free Communication</b> presented at the ERA-EDTA Congress, June 6-9, 2020 in Milan, Italy
The Dual Endothelin ETA and Angiotensin AT1 Receptor Blocker Sparsentan Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy	<b>E- poster presented</b> at the ERA-EDTA Congress, June 6-9, 2020 in Milan, Italy
The Dual AT <sub>1</sub> R/ET <sub>A</sub> R Blocker Sparsentan Prevents Hearing Loss and Renal disease in Alport Mice	Poster presented at ARO 2020 Congress held January 25-29, 2020  Abstract available at: <a href="https://www.aro.org/assets/2020_MWM/ARO%202020%20Abstracts_1-21-20-Web.pdf">https://www.aro.org/assets/2020_MWM/ARO%202020%20Abstracts_1-21-20-Web.pdf</a>

## 2019

Title	Meeting/Citation
Impact of Sparsentan on Quality of Life (QoL) in Focal Segmental Glomerulosclerosis (FSGS) Patients in DUET: An Interim Analysis	Poster presented at ASN Kidney Week 2019 on November 7, 2019  Abstract available at: <a href="https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controllId=3232957">https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controllId=3232957</a>
Change in Proteinuria as a Surrogate Endpoint for GFR Slope – Individual Patient Meta-Analysis of 12 RCTs in IgA Nephropathy	Oral presentation at ASN Kidney Week 2019 presented on November 7, 2019  Abstract available at: <a href="https://www.asn-online.org/education/ki2_dneyweek/2019/program-abstract.aspx?controllId=3235455">https://www.asn-online.org/education/ki2_dneyweek/2019/program-abstract.aspx?controllId=3235455</a>

	<i>Abstract submitted by Tufts collaborators, resulting from sponsored collaboration work</i>
The Dual AT1R/ETAR Blocker Sparsentan Slows Renal Disease, Improves Lifespan, and Prevents Hearing Loss in Alport Mice	Poster presented at ASN Kidney Week 2019 on November 7, 2019  Abstract available at: <a href="https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3230279">https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3230279</a>
Endothelin type A receptor activation: a drug target that may address both glomerular and inner ear pathologies in Alport syndrome	Poster & Oral presentations at the International Workshop on Alport Syndrome, 22-24 October 2019 in Siena, Italy
DUET Pediatric Subset: a Phase 2 Study Evaluating Sparsentan in Focal Segmental Glomerulosclerosis (FSGS)	Oral presentation at IPNA Congress presented on October 18, 2019  Ken Lieberman, Kevin Meyers, Ed Murphy, Tarak Srivastava, Howard Trachtman, Radko Komers. DUET pediatric subset: a phase 2 study evaluating sparsentan in focal segmental glomerulosclerosis (FSGS). Abstract presented at the 18th Congress of the International Pediatric Nephrology Association, Venice (Italy), October 2019. <i>Pediatr Nephrol</i> 34, 1821–2260 (2019). doi:10.1007/s00467-019-04325-4  Abstract available at: <a href="https://rdcu.be/bZO25">https://rdcu.be/bZO25</a>
No impact of newly initiated immunosuppressive therapy observed on long-term antiproteinuric effect of sparsentan in focal segmental glomerulosclerosis: interim 84-week analysis of the DUET trial	Poster Presentation at WCN Meeting on April 14, 2019 Poster Board SUN-037  Published in <i>KI Reports</i> July 2019 Volume 4, Issue 7, Supplement, S168-S169 <a href="https://doi.org/10.1016/j.ekir.2019.05.432">https://doi.org/10.1016/j.ekir.2019.05.432</a>  Abstract available at: <a href="https://www.kireports.org/article/S2468-0249(19)30627-8/fulltext">https://www.kireports.org/article/S2468-0249(19)30627-8/fulltext</a>
Protective effects of sparsentan from proliferative glomerular injury induced by administration of human immune complexes in a murine model of experimental IgA nephropathy	Poster Presentation at WCN Meeting on April 13, 2019 Poster Board SAT-010  Published in <i>KI Reports</i> July 2019 Volume 4, Issue 7, Supplement, S1-S438 <a href="https://doi.org/10.1016/j.ekir.2019.05.031">https://doi.org/10.1016/j.ekir.2019.05.031</a>  Abstract available at: <a href="https://www.kireports.org/article/S2468-0249(19)30226-8/fulltext">https://www.kireports.org/article/S2468-0249(19)30226-8/fulltext</a>
Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS):	Poster presentation at NKF Spring Meeting May 8-12, 2019  Abstract available at:

Design of the Phase 3 DUPLEX Study	<a href="https://casehippo.com/Symposium/national-kidney-foundation-2019-spring-clinical-meetings#!/gallery/abstracts?abstractId=337">https://casehippo.com/Symposium/national-kidney-foundation-2019-spring-clinical-meetings#!/gallery/abstracts?abstractId=337</a>
<b>2018</b>	
<b>Title</b>	<b>Meeting/Citation</b>
Long-term Effects of Sparsentan, a Dual Angiotensin and Endothelin Receptor Antagonist in Primary Focal Segmental Glomerulosclerosis (FSGS): Interim 84-Week Analysis of the DUET Trial	<p>Oral presentation at the ASN Kidney Week Annual Meeting presented October 26, 2018 in San Diego, CA</p> <p>Session Title: Glomerular Diseases: Clinical, Outcomes, and Trials [OR1203-1]  Session Date, Time: October 26, 2018 from 4:30 PM to 6:30 PM  Session Room: 24A (San Diego Convention Center)  Abstract Publication #: FR-OR087  Presentation Time: 6:18 PM to 6:30 PM</p> <p>Citation:  Hogan J, et al. Long-Term Effects of Sparsentan, a Dual Angiotensin and Endothelin Receptor Antagonist in Primary Focal Segmental Glomerulosclerosis (FSGS): Interim 84-Week Analysis of the DUET Trial (Abstract FR-OR087). <i>J Am Soc Nephrol.</i> 2018;29:61.</p> <p>Abstract available at:  <a href="https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3021798">https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3021798</a></p>
Sparsentan, a Dual Angiotensin II Type 1 (AT <sub>1</sub> ) and Endothelin Type A (ET <sub>A</sub> ) Receptor Antagonist, Prevents Renal Disease in COL4A3 -/- Autosomal Alport Mice	<p>Poster presented at the ASN Kidney Week Annual Meeting held October 26, 2018 in San Diego, CA</p> <p>Genetic Diseases of the Kidney Non-Cystic II  Session Date and Time: 10:00 – 12:00pm October 26  Poster #: FR-PO624</p> <p>Abstract available at:  <a href="https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3022017">https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3022017</a></p>
Effect of Sparsentan, a Dual Angiotensin II Type 1 (AT <sub>1</sub> ) and Endothelin Type A (ET <sub>A</sub> ) Receptor Antagonist, in the Rat anti-Thy1 Model of Glomerulonephritis	<p>Oral presentation and e-poster at the International Symposium on IgA Nephropathy Meeting held September 27-29, 2018 in Buenos Aires, Argentina</p> <p>Abstract #0054  Ballroom: Cabildo  Time: 16:35 - 17:55</p> <p>Abstract available at:  Jenkinson C et al. <i>Kidney Dis</i> 2018;4:141. <a href="https://doi.org/10.1159/000492806">https://doi.org/10.1159/000492806</a></p> <p>Meeting summaries:  <i>Kidney Dis</i> 2018;4:145–194. <a href="https://doi.org/10.1159/000492807">https://doi.org/10.1159/000492807</a></p>

<p>PROTECT in Immunoglobulin A Nephropathy (IgAN): Study Design of a Phase 3, Randomized, Double-blind, International, Active-controlled Study of the Efficacy and Safety of Sparsentan</p>	<p>Oral presentation and e-poster at the International Symposium on IgA Nephropathy Meeting held September 27-29, 2018 in Buenos Aires, Argentina</p> <p>Abstract #0055 Ballroom: Cabildo Time: 11:00 - 11:30</p> <p>Abstract available at: Barratt J et al. <i>Kidney Dis</i> 2018;4:142. <a href="https://doi.org/10.1159/000492806">https://doi.org/10.1159/000492806</a></p> <p>Meeting summaries: <i>Kidney Dis</i> 2018;4:145–194. <a href="https://doi.org/10.1159/000492807">https://doi.org/10.1159/000492807</a></p>
<p>An Early Decrease in Proteinuria is Associated With A Slowing in the Longer-Term Rate of Decline of Estimated Glomerular Filtration Rate in Immunoglobulin A Nephropathy: Observations from 2 UK Registries</p>	<p>E-poster at the International Symposium on IgA Nephropathy Meeting held September 27-29, 2018 in Buenos Aires, Argentina</p> <p>Abstract available at: Carroll K et al. <i>Kidney Dis</i> 2018;4:134. <a href="https://www.karger.com/Article/Abstract/492806">https://www.karger.com/Article/Abstract/492806</a></p> <p>Full citation: 15th International Symposium on IgA Nephropathy – IIgANN 2018, Buenos Aires, September 27-29, 2018: Abstracts. <i>Kidney Dis</i> 2018;4:107-144. doi: 10.1159/000492806</p> <p><i>POSTER IS NOT SPONSORED BY RETROPHIN, WRITING SUPPORT PROVIDED BY RETROPHIN</i></p>
<p>Newly Administered Immunosuppressive Therapy (IST) Has No Impact on Long-term Antiproteinuric Effect of Sparsentan (SPAR), a Dual Angiotensin and Endothelin Receptor Antagonist, in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS): Interim Analysis of the DUET Trial</p>	<p>Poster presented at ERA-EDTA Annual Meeting, held May 24-27 in Copenhagen</p> <p>Abstract available online at: <a href="https://doi.org/10.1093/ndt/gfy104.FP129">https://doi.org/10.1093/ndt/gfy104.FP129</a></p> <p><i>Nephrology Dialysis Transplantation</i>, Volume 33, Issue suppl_1, 1 May 2018, Pages i20</p>
<b>2017</b>	
<p><b>Title</b></p>	<p><b>Meeting/Citation</b></p>
<p>Effects of CYP3A4 and P-glycoprotein (P-gp) Inhibition by Itraconazole (IT) and Cyclosporine (CsA), Individually, on the Pharmacokinetics of Sparsentan (RE-021), a First-in-Class, Potent, Orally-active Dual-acting Angiotensin II</p>	<p>Poster presented at ACCP Annual Meeting September 17-19 in San Diego</p> <p>Abstract available at: <a href="http://onlinelibrary.wiley.com/doi/10.1002/cpdd.385/abstract">http://onlinelibrary.wiley.com/doi/10.1002/cpdd.385/abstract</a></p> <p><i>Clinical Pharmacology in Drug Development</i> 2017; Volume 6 (Issue S1): 3-72</p>



(Type 1) Receptor Blocker (ARB) and Endothelin Type A Receptor Antagonist	
A Clinical Study Assessing Potential Induction of CYP3A4 and CYP2B6 by Steady-State Sparsentan (RE-021), a First-in-Class, Potent, Dual Angiotensin II Blocker (ARB) and Endothelin Type A Receptor Antagonist, Using Midazolam and Bupropion as <i>In Vivo</i> Probes	<p>Poster presented at ACCP Annual Meeting September 17-19 in San Diego</p> <p>Abstract available at:  <a href="http://onlinelibrary.wiley.com/doi/10.1002/cpdd.385/abstract">http://onlinelibrary.wiley.com/doi/10.1002/cpdd.385/abstract</a></p> <p>Clinical Pharmacology in Drug Development 2017; Volume 6 (Issue S1): 3-72</p>
Semi-Quantitation of Sparsentan Circulating Metabolites in Focal Segmental Glomerulosclerosis (FSGS) Patients Using Radioactivity/Mass Spectrometry Peak Area Response Factor Analysis	<p>Poster presented at ISSX Annual Meeting September 24-28, 2017 Providence, RI</p> <p>Abstract available at:  <a href="http://issx.confex.com/issx/21NA/webprogram/Paper38183.html">http://issx.confex.com/issx/21NA/webprogram/Paper38183.html</a></p>
Sparsentan Pharmacokinetics and Pharmacodynamics as the Basis of Dose Selection for Primary Focal Segmental Glomerular Sclerosis (FSGS)	<p>Poster presented at ASN Nov 4, 2017</p> <p>Abstract available at:  <a href="https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2771214">https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2771214</a></p> <p>Session Title: 1601-PO01 Pharmacokinetics, Pharmacodynamics, Pharmacogenomics  Session Date, Time: November 4, 2017 from 10:00 AM to 12:00 PM</p>
Long-term effect of sparsentan (SPAR), a dual angiotensin and endothelin receptor antagonist, on proteinuria in patients with primary FSGS: Interim analysis of the DUET trial	<p>Oral presentation presented at ASN Nov 3, 2017</p> <p>Abstract available at:  <a href="https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2771308">https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2771308</a></p> <p>Session Title: 1005-OR02 Clinical Glomerular Disorders: Clinical Translational Science  Session Date, Time: November 3, 2017 from 4:30 - 6:30 PM  Session Room: Room 292 (Morial Convention Center)  Presentation Times: 5:30 PM to 5:42 PM</p>
Dual Angiotensin II (Ang II) AT1 and Endothelin (ET) Type A Receptor Inhibition with Sparsentan in Primary Focal Segmental	<p>Oral presentation at the Fifteenth International Conference on Endothelin, Prague, Czech Republic, October 4-7, 2017</p>



Glomerulosclerosis (FSGS): DUET Trial	
Antiproteinuric Effect of Sparsentan, A Dual Angiotensin II and Endothelin Type A Receptor Antagonist, In Patients with Primary Focal Segmental Glomerulosclerosis (FSGS): A Subgroup Analysis of the DUET Trial	<p>Oral presentation at ERA Jun 2017</p> <p>Abstract available at: <i>Nephrology Dialysis Transplantation</i>, Volume 32, Issue suppl_3, 1 May 2017, Pages iii97, <a href="https://doi.org/10.1093/ndt/gfx134.TO042">https://doi.org/10.1093/ndt/gfx134.TO042</a></p>
<i>In Vitro</i> Evaluation of Induction of Cytochrome P450 Enzymes by sparsentan and Effects on its Metabolism by Potential Co-administered Drugs	<p>Poster presented at ERA Jun 2017</p> <p>Abstract available at: <i>Nephrology Dialysis Transplantation</i>, Volume 32, Issue suppl_3, 1 May 2017, Pages iii146–iii147, <a href="https://doi.org/10.1093/ndt/gfx141.SP124">https://doi.org/10.1093/ndt/gfx141.SP124</a></p>
<b>2016</b>	
Efficacy and Safety of Sparsentan Compared with Irbesartan in Patients with Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)	<p>Oral presentation at ASN 2016</p> <p>Trachtman H, Nelson P, Radko K on behalf of the DUET Investigators. Efficacy and Safety of Sparsentan, a Dual Angiotensin II and Endothelin Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis: A Phase 2 Trial (DUET). <i>J Am Soc Nephrol</i> 2016: (27) Abstract edition: 1165.</p> <p>Abstract available at: <a href="https://www.asn-online.org/api/download/?file=/education/kidneyweek/archives/KW16Abstracts.pdf">https://www.asn-online.org/api/download/?file=/education/kidneyweek/archives/KW16Abstracts.pdf</a></p>
Antihypertensive Effects of Sparsentan, a Dual Angiotensin II and Endothelin Type A Receptor Antagonist	<p>Poster presented at ASN Nov 2016</p> <p>Radko K, Shih A, Belder R. Antihypertensive Effects of Sparsentan, a Dual Angiotensin II and Endothelin Type A Receptor Antagonist. <i>J Am Soc Nephrol</i> 2016: (27) Abstract edition: SA-PO685.</p>
Renal Pharmacology and Preclinical Attributes of Sparsentan, a Dually Active Endothelin-A and Angiotensin 1 Receptor Antagonist	<p>Poster presented at ASN Nov 2016</p> <p>Leach K, Pan-Zhou X-R, Deats W, Beconi M. Renal Pharmacology and Preclinical Attributes of Sparsentan, a Dually Active Endothelin A and Angiotensin 1 Receptor Antagonist. <i>J Am Soc Nephrol</i> 2016: (27) Abstract edition: 134.</p> <p>Abstract available at: <a href="https://www.asn-online.org/api/download/?file=/education/kidneyweek/archives/KW16Abstracts.pdf">https://www.asn-online.org/api/download/?file=/education/kidneyweek/archives/KW16Abstracts.pdf</a></p>

<p>Sparsentan In Vitro Metabolism and Effects of Food, Gender, Age, and Multiple-dose Escalation on its Pharmacokinetics in Healthy Subjects</p>	<p>Poster Presented at ASN Nov 2016</p> <p>Pan-Zhou X-R, Leach K, Beconi M. Pharmacokinetics of Sparsentan in Healthy Subjects: In Vitro Metabolism and Effects of Food, Gender, Age, and Multiple-Dose Escalation. <i>J Am Soc Nephrol</i> 27: 2016, pg. 748</p> <p>Abstract available at:  <a href="https://www.asn-online.org/api/download/?file=/education/kidneyweek/archives/KW16Abstracts.pdf">https://www.asn-online.org/api/download/?file=/education/kidneyweek/archives/KW16Abstracts.pdf</a></p>
--	--

**MANUSCRIPTS**

<b>Title</b>	<b>Citation/Progress</b>
<p>Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease</p>	<p>Komers R, Plotkin H. <i>Am J Physiol Regul Integr Comp Physiol</i> 2016;310: R877–R884</p> <p>Available here:  <a href="https://www.physiology.org/doi/full/10.1152/ajpregu.00425.2015">https://www.physiology.org/doi/full/10.1152/ajpregu.00425.2015</a></p>
<p>Efficacy and Safety of Sparsentan Compared with Irbesartan in Patients with Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)</p>	<p>Published in <i>KI Reports</i> (2017)</p> <p>Komers R, et al. <i>Kidney Inter Reports</i>. 2017;2(4):654-664.  <a href="https://doi.org/10.1016/j.ekir.2017.02.019">https://doi.org/10.1016/j.ekir.2017.02.019</a></p> <p>Available here:  <a href="http://www.kireports.org/article/S2468-0249(17)30052-9/fulltext">http://www.kireports.org/article/S2468-0249(17)30052-9/fulltext</a></p>
<p>DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS</p>	<p>Published in <i>JASN</i> (September 2018)</p> <p>Trachtman H, et al. <i>J Am Soc Nephrol</i>. 2018;29(11):2745-2754. DOI:  <a href="https://doi.org/10.1681/ASN.2018010091">https://doi.org/10.1681/ASN.2018010091</a></p> <p>Available here:  <a href="https://jasn.asnjournals.org/content/early/2018/10/24/ASN.2018010091#sec-17">https://jasn.asnjournals.org/content/early/2018/10/24/ASN.2018010091#sec-17</a></p>
<p>Implementing the Kidney Health Initiative surrogate efficacy endpoint in patients with immunoglobulin A nephropathy: the PROTECT trial</p>	<p>Published in <i>KI Reports</i> (November 2019)</p> <p>Barratt J, Rovin B, Diva U, Mercer A, Komers R; PROTECT Study Design Group. Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial). <i>Kidney Int Rep</i>. 2019; 4(11):1633-1637.</p> <p>Available here:  <a href="https://www.kireports.org/article/S2468-0249(19)31463-9/fulltext">https://www.kireports.org/article/S2468-0249(19)31463-9/fulltext</a></p>
<p>Randomized, Multicenter, International, Double-Blind,</p>	<p>Published in <i>KI Reports</i> (Jan 2020)</p>

<p>Active-Controlled Study of Sparsentan in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS): Design of the Phase 3 DUPLEX Study</p>	<p>Komers R, Diva U, Inrig JK, Loewen A, Trachtman H, Rote WE. Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis. <i>Kidney Int Rep.</i> 2020;5(4):494-502.</p> <p>Available here:  <a href="https://www.kireports.org/article/S2468-0249(20)30003-6/fulltext">https://www.kireports.org/article/S2468-0249(20)30003-6/fulltext</a></p>
<p>Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy.</p>	<p>Published in <i>Drugs of the Future</i> (Feb 2020)</p> <p>Trachtman, H., Hogan, J.J., Tesar, V., Komers, R. Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy. <i>Drugs Fut</i> 2020, 45(2): 79</p> <p>Link to journal citation:  <a href="#">Clarivate Journals on the Web</a></p>
<p>Efficacy and safety of immunosuppressive therapy in primary FSGS: A systematic review and meta-analysis</p>	<p>Published in <i>Kidney Medicine</i> (Aug 2022)</p> <p>Dawn J. Caster, Barbara Magalhaes, Natali Pennese, Andrea Zaffalon, Marina Faiella, Kirk N. Campbell, Jai Radhakrishnan, Vladmir Tesar, Howard Trachtman</p> <p>Link: DOI: <a href="https://doi.org/10.1016/j.xkme.2022.100501">https://doi.org/10.1016/j.xkme.2022.100501</a></p>
<p>Efficacy and Safety of ACE inhibitor and ARB Therapies in Primary FSGS Treatment: A Systematic Review and Meta-analysis</p>	<p>Published in <i>Kidney Medicine</i> (Mar 2022)</p> <p>Campbell K, Pennese N, Zaffalon A, Magalhaes B, Faiella M, Caster D, Radhakrishnan J, Tesar V, Trachtman H. Efficacy and Safety of ACE inhibitor and ARB Therapies in Primary FSGS Treatment: A Systematic Review and Meta-analysis</p> <p>Link: DOI: <a href="https://doi.org/10.1016/j.xkme.2022.100457">https://doi.org/10.1016/j.xkme.2022.100457</a></p>
<p>IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study</p>	<p>Accepted by <i>Kidney International Reports</i>, Dec 2022</p> <p>Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hidido JL Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernán Trimarchi, and Vlado Perkovic on behalf of the PROTECT investigators</p> <p>Link: <a href="https://www.kireports.org/article/S2468-0249(23)01195-6/fulltext">https://www.kireports.org/article/S2468-0249(23)01195-6/fulltext</a></p>
<p>Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug-Drug Interaction Study in Healthy Adults</p>	<p>Accepted by <i>Clinical Pharmacology in Drug Development</i>, Feb 2023</p> <p>Shang-Chiung Chen, Danlin Cai, Claire Winnett, Mai Nguyen, Neeraj Verma, Kai Liu, and Priscila Preciado</p> <p>Link: <a href="https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.1231">https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.1231</a></p>
<p>Long-term Outcomes in IgA Nephropathy</p>	<p>Accepted by <i>Clinical Journal of the American Society of Nephrology</i>, Feb 2023</p>

	<p>David Pitcher, Fiona Braddon, Bruce Hendry, Alex Mercer, Kate Osmaston, Moin A. Saleem, Retha Steenkamp, Katie Wong, Neil Turner, Kaijun Wang, Daniel P. Gale, Jonathan Barratt</p> <p>Link:</p>
<p>Sparsentan in Patients with IgA Nephropathy: A Prespecified Interim Analysis from a Randomised Double-Blind Active-Controlled Clinical Trial</p>	<p>Published in <i>The Lancet</i>, April 2023</p> <p>Hiddo JL Heerspink, Jai Radhakrishnan, Charles E. Alpers, Jonathan Barratt, Stewart Bieler, Ulysses Diva, Jula Inrig, Radko Komers, Alex Mercer, Irene L. Noronha, Michelle N. Rheault, William Rote, Brad Rovin, Howard Trachtman, Hernán Trimarchi, Muh Geot Wong, Vlado Perkovic, and PROTECT investigators</p> <p>Link (NOT Open Access):  <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext</a></p>
<p>Humanistic and economic burden of IgA-nephropathy: systematic literature reviews and narrative synthesis</p>	<p>Accepted by <i>PharmacoEconomics – Open</i>, April 2023</p> <p>Kenar D. Jhaveri, Mark E. Bensink, Martin Bunke, Jonathon A. Briggs, David M.W. Cork, Anushya Jeyabalan</p> <p>Link: coming soon</p>
<p>Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice</p>	<p>Accepted by <i>The Journal of Pathology</i>, April 2023</p> <p>Dominic Cosgrove, Michael Anne Gratton, Jacob Madison, Denise Vosik, Gina Samuelson, Daniel Meehan, Duane Delimont, Grady Phillips, Brendan Smyth, Tiziano Pramparo, Diana Jarocki, Mai Nguyen, Radko Komers and Celia Jenkinson</p> <p>Link: coming soon</p>